Preserving Ocular Surface Health
Intraocular pressure (IOP) is a major risk factor in the onset of visual field loss due to glaucoma. The higher the IOP, the greater the likelihood of visual field loss and ocular nerve damage.1
TIMOPTIC®, when applied to the eye, acts to reduce both elevated and normal IOP.1
Unlike other treatments, TIMOPTIC® in OCUDOSE® is not just BAK-free — it’s a completely preservative-free glaucoma treatment that doesn’t compromise the ocular surface.2
- Studies have shown that a preservative-free timolol eye drop is less toxic for the ocular surface3
Preservative-free formulation minimizes inflammatory activation of
interleukin-1β (IL-1β).2
- IL-1β is a key regulator of ocular surface inflammation that can lead to clinical ocular surface alterations4
- Preserved therapy resulted in significantly greater increase in IL-1β concentration4
Repeated use of glaucoma medication with preservatives like BAK can have detrimental effects on the ocular tissue.5
- For glaucoma patients at risk for ocular surface damage, preservative-free medication may reduce side effects and increase medication tolerability
INDICATIONS AND USAGE
Preservative-free TIMOPTIC® in OCUDOSE® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free TIMOPTIC® in OCUDOSE® may be used when a patient is sensitive to the preservative in Timoptic (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.
IMPORTANT SAFETY INFORMATION
Timoptic is contraindicated in patients with: bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; hypersensitivity to any component of this product.
This drug is absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. Severe respiratory or cardiac reactions, including death, have been reported following systemic or ophthalmic administration of timolol maleate. Timoptic should be used with caution in patients with cerebrovascular insufficiency.
The most frequently reported adverse experiences have been burning and stinging upon instillation.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
References: 1. Timoptic (timolol maleate ophthalmic solution) in Ocudose (dispenser) [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2009. 2. Manni G, Centofanti M, Oddone F, Parravano M, Bucci MG. Interleukin-1β tear concentration in glaucomatod/us and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol. 2005;139:72-77. 3. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418-423. 4. Li DQ, Tseng SC. Three patterns of cytokine expression potentially involved in epithelial-fibroblast interactions of human ocular surface. J Cella Physiol. 1995;163:61-79. 5. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
